Analysts’ Top Healthcare Picks: Pulse Biosciences (PLSE), Aslan Pharmaceuticals Ltd (ASLN)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulse Biosciences (PLSEResearch Report), Aslan Pharmaceuticals Ltd (ASLNResearch Report) and Provention Bio Inc (PRVBResearch Report) with bullish sentiments.

Pulse Biosciences (PLSE)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pulse Biosciences, with a price target of $26. The company’s shares closed last Monday at $11.54.

Ramakanth said:

“We maintain our Buy rating and lower our 12-month price target to $26.00 per share, down from $27.00. We derive our price target based on a risk-adjusted NPV (rNPV) analysis of projected CellFX revenues through 2030 assuming a 12.5% discount rate and a 2% terminal growth rate.”

According to TipRanks.com, Ramakanth is ranked 0 out of 5 stars with an average return of -11.7% and a 27.4% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.

Currently, the analyst consensus on Pulse Biosciences is a Moderate Buy with an average price target of $26.

See today’s analyst top recommended stocks >>

Aslan Pharmaceuticals Ltd (ASLN)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals Ltd, with a price target of $9. The company’s shares closed last Monday at $2.68, close to its 52-week low of $2.51.

Chen wrote:

“Our 12-month price target is based on an estimated market value of the firm at $309M. This includes a discounted cash flow analysis based asset value of $323M for varlitinib and ASLAN003, using a 15% discount rate and 0.5% terminal growth rate, excluding $14M debt and assuming 171.7M shares outstanding at the end of 2Q20. Our probabilities of success are 65% for varlitinib in global BTC (50% in in AML.”

According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -19.5% and a 26.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aslan Pharmaceuticals Ltd with a $9 average price target.

Provention Bio Inc (PRVB)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Provention Bio Inc, with a price target of $20. The company’s shares closed last Monday at $9.80.

Selvaraju said:

“We reiterate our Buy rating and 12-month price target of $20.00 per share. Timeline to regulatory submission of teplizumab to be defined. We draw investors’ attention to the fact that Provention Bio could conduct a meeting with the FDA before the end of this year in order to finalize the requirements to file for approval of teplizumab in prevention of type 1 diabetes (T1D). As a reminder, teplizumab generated highly favorable clinical efficacy data in a proof-of-concept at-risk study that focused on individuals at significantly elevated risk of developing T1D; the principal takeaway from this trial was that teplizumab therapy—administered as a short-course 14-day regimen involving once-daily intravenous infusions —significantly delayed the onset of disease by roughly two years.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -10.7% and a 27.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Provention Bio Inc with a $25 average price target, which is a 160.7% upside from current levels. In a report issued on August 5, Chardan Capital also reiterated a Buy rating on the stock with a $20 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.